Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 2
1989 1
1990 2
1991 3
1992 5
1993 2
1994 1
1995 2
1997 3
1998 2
1999 3
2000 3
2001 10
2002 4
2003 13
2004 3
2005 5
2006 4
2007 5
2008 5
2009 4
2010 7
2011 9
2012 3
2013 7
2014 11
2015 12
2016 13
2017 13
2018 18
2019 41
2020 30
2021 39
2022 43
2023 25
2024 13

Text availability

Article attribute

Article type

Publication date

Search Results

336 results

Results by year

Filters applied: . Clear all
Page 1
Tafenoquine: the new kid on the block.
Chen V, Daily JP. Chen V, et al. Curr Opin Infect Dis. 2019 Oct;32(5):407-412. doi: 10.1097/QCO.0000000000000574. Curr Opin Infect Dis. 2019. PMID: 31305490 Review.
PURPOSE OF REVIEW: This is a review of tafenoquine, a new antimalarial drug. Here we examine the recent literature supporting the use of tafenoquine and summarize the opportunities and challenges for its well tolerated use worldwide. ...In addition, studies on ta …
PURPOSE OF REVIEW: This is a review of tafenoquine, a new antimalarial drug. Here we examine the recent literature supporting the use …
Tafenoquine and G6PD: a primer for clinicians.
Chu CS, Freedman DO. Chu CS, et al. J Travel Med. 2019 Jun 1;26(4):taz023. doi: 10.1093/jtm/taz023. J Travel Med. 2019. PMID: 30941413 Free PMC article. Review.
RESULTS: Tafenoquine should only be given to those with G6PD activity >70% of the local population median. ...This review provides actions that can be taken to diagnose and manage hemolysis when tafenoquine is given inadvertently to ineligible individuals. CONCLU …
RESULTS: Tafenoquine should only be given to those with G6PD activity >70% of the local population median. ...This review provides …
Tafenoquine Therapy and G6PD Genotype.
Dean L, Kane M. Dean L, et al. 2020 Oct 13. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kattman BL, Malheiro AJ, editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012–. 2020 Oct 13. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kattman BL, Malheiro AJ, editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012–. PMID: 33048487 Free Books & Documents. Review.
Tafenoquine is the second drug of its kind (with hypnozoiticidal activity) to be approved by the FDA. ...This can lead to a potentially life-threatening deficiency of mature red blood cells (hemolytic anemia). The FDA-approved drug label for tafenoquine states that …
Tafenoquine is the second drug of its kind (with hypnozoiticidal activity) to be approved by the FDA. ...This can lead to a potential …
Tafenoquine.
[No authors listed] [No authors listed] 2019 May 1. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2019 May 1. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 30222296 Free Books & Documents. Review.
No information is available on the use of tafenoquine during breastfeeding. Tafenoquine can cause hemolysis in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. If tafenoquine is needed by the mother, testing the mother and infant for G6PD de …
No information is available on the use of tafenoquine during breastfeeding. Tafenoquine can cause hemolysis in patients with g …
Tafenoquine: First Global Approval.
Frampton JE. Frampton JE. Drugs. 2018 Sep;78(14):1517-1523. doi: 10.1007/s40265-018-0979-2. Drugs. 2018. PMID: 30229442 Review.
Subsequently, in August 2018, tafenoquine was approved in the USA for the prophylaxis of malaria in patients aged 18 years. This article primarily summarizes the milestones in the development of tafenoquine leading to its first global approval for the radical cure o …
Subsequently, in August 2018, tafenoquine was approved in the USA for the prophylaxis of malaria in patients aged 18 years. This arti …
Tafenoquine.
[No authors listed] [No authors listed] 2019 Apr 10. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2019 Apr 10. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31643747 Free Books & Documents. Review.
Tafenoquine is an aminoquinoline that is used in combination with other antimalarials for the prevention of relapse of Plasmodium vivax malaria and by itself as prophylaxis against all species of malaria. Tafenoquine has been linked to low rates of transient and asy …
Tafenoquine is an aminoquinoline that is used in combination with other antimalarials for the prevention of relapse of Plasmodium viv …
Tafenoquine for the treatment of Plasmodium vivax malaria.
Llanos-Cuentas A, Manrrique P, Rosas-Aguirre A, Herrera S, Hsiang MS. Llanos-Cuentas A, et al. Expert Opin Pharmacother. 2022 May;23(7):759-768. doi: 10.1080/14656566.2022.2058394. Epub 2022 Apr 13. Expert Opin Pharmacother. 2022. PMID: 35379070 Review.
Primaquine, an 8-aminoquinoline drug, has been the standard of care for decades to treat liver-stage P. vivax malaria; however, it requires long treatment regimens (one to two weeks) that lead to poor adherence and thus clinical relapses. Tafenoquine (TFQ), a newly availab …
Primaquine, an 8-aminoquinoline drug, has been the standard of care for decades to treat liver-stage P. vivax malaria; however, it requires …
Tafenoquine succinate for malaria prevention.
[No authors listed] [No authors listed] Aust Prescr. 2019 Jun;42(3):110-111. doi: 10.18773/austprescr.2019.034. Epub 2019 Apr 24. Aust Prescr. 2019. PMID: 31363314 Free PMC article. Review. No abstract available.
Tafenoquine for Plasmodium vivax malaria: Concerns regarding efficacy & safety.
Sharma J, Gautam CS, Singh H, Singh J. Sharma J, et al. Indian J Med Res. 2021 Jun;154(6):797-805. doi: 10.4103/ijmr.IJMR_1167_19. Indian J Med Res. 2021. PMID: 35662084 Free PMC article. Review.
Another problem associated with PQ is the poor adherence rate to the 14-day treatment regimen. Single-dose tafenoquine (TQ), an 8-aminoquinoline, has recently been approved by the U.S. ...
Another problem associated with PQ is the poor adherence rate to the 14-day treatment regimen. Single-dose tafenoquine (TQ), an 8-ami …
Tafenoquine for preventing relapse in people with Plasmodium vivax malaria.
Rajapakse S, Rodrigo C, Fernando SD. Rajapakse S, et al. Cochrane Database Syst Rev. 2015 Apr 29;2015(4):CD010458. doi: 10.1002/14651858.CD010458.pub2. Cochrane Database Syst Rev. 2015. PMID: 25921416 Free PMC article. Updated. Review.
In addition, there is some evidence of parasite resistance to the drug. Tafenoquine is a new alternative with a longer half-life. OBJECTIVES: To assess the effects of tafenoquine in people with P. vivax infection. ...Tafenoquine versus primaquine Two of the i …
In addition, there is some evidence of parasite resistance to the drug. Tafenoquine is a new alternative with a longer half-life. OBJ …
336 results